No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading into the new year. Let's consider three that are among my favorites to buy: ...

Steel is a cyclical sector, and several catalysts could propel Nucor stock even higher through the cycle. However, there are ...

Reale talks living in New Jersey, her favorite movie, and the superpower that could make a difference on the field.

Lilly Clarke rejoins the City of Garland as the new Managing Director of Human Resources, bringing extensive municipal HR ...

Together, these stocks offer you a balanced mix of growth and safety. These companies span a number of industries, and many ...

Retatrutide, Eli Lilly’s triple-hormone obesity drug, delivers up to 28.7% weight loss and major knee pain relief in ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show ...

Antis’ Lilly Gerwert became the 16th player in program history to reach the 1,000 career point mark as she recorded a ...

But even as Ozempic enters India, there is a growing sense globally that Novo may have already lost the obesity drug war to Mounjaro, Eli Lilly’s blockbuster that has become India’s top-selling drug ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a +1.8% change compared to its last close.